Trial Profile
Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2022
Price :
$35
*
At a glance
- Drugs Sertraline (Primary)
- Indications Premenstrual dysphoric disorder
- Focus Therapeutic Use
- 09 Dec 2021 Status changed from recruiting to completed.
- 05 Nov 2019 Planned number of patients changed from 60 to 127.
- 25 May 2016 New trial record